Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently received Food and Drug Administration (FDA) approval for obesity management. However, the causal relationship between GLP-1RAs and psychiatric and neurodevelopmental conditions remains unclear. Methods We used Men...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-05-01
|
| Col·lecció: | BMC Psychiatry |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12888-025-06914-0 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
